Company Description
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity.
The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007.
Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
| Country | United Kingdom |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 88 |
| CEO | Iain Ross |
Contact Details
Address: 12 Hammersmith Grove London, W6 7AP United Kingdom | |
| Phone | 44 20 3457 6900 |
| Website | silence-therapeutics.com |
Stock Details
| Ticker Symbol | SLN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001479615 |
| CUSIP Number | 82686Q101 |
| ISIN Number | US82686Q1013 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D | Interim Chief Executive Officer and Chairman of the Board |
| Rhonda L. Hellums | Executive Vice President, Chief Financial Officer, Secretary and Executive Director |
| Dr. Steven J. Romano M.D. | Executive Vice President and Chief Research and Development Officer |
| Dr. Marie Wikstrom Lindholm Ph.D. | Chief Scientific Officer |
| Gem Gokmen Hopkins | Head of IR and Corporate Communications |
| Jaimin B. Shah | SVice President and General Counsel |
| J.P. Gabriel | Chief Technical Operations Officer |
| Curtis Rambaran M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2026 | 8-K | Current Report |
| Jun 16, 2026 | 8-K | Current Report |
| Jun 11, 2026 | 8-K | Current Report |
| May 27, 2026 | EFFECT | Notice of Effectiveness |
| May 27, 2026 | 424B5 | Filing |
| May 18, 2026 | 8-K | Current Report |
| May 18, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| May 7, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | 8-K | Current Report |
| Apr 29, 2026 | ARS | Filing |